Zevra Therapeutics (ZVRA) Receivables - Other (2015 - 2024)
Zevra Therapeutics' (ZVRA) quarterly Receivables - Other came in at $333000.0 in Q4 2024, down 73.53% YoY from $1.3 million in Q1 2024, and down 73.53% on a QoQ basis from $1.3 million in Q4 2023.
Zevra Therapeutics (ZVRA) Receivables - Other (2015 - 2024) Analysis & Trends
Zevra Therapeutics (ZVRA) has 10 years of Receivables - Other data on file, last reported at $333000.0 in Q4 2024.
- Quarterly Receivables - Other fell 73.53% year-over-year to $333000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $333000.0 (down 73.53% YoY) and the FY2024 annual result came in at $333000.0, down 73.53% from the prior year.
- Receivables - Other eased to $333000.0 in Q4 2024, from $1.3 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.3 million in Q4 2023 to a low of $107000.0 in Q4 2021.
- A 5-year average of $543625.0 and a median of $366500.0 in 2022 frame the typical range for Receivables - Other.
- Annual changes were most pronounced in 2022 — Receivables - Other jumped 941.12% — and 2024, when it plunged 73.53%.
- Tracing ZVRA's Receivables - Other over 5 years: stood at $137000.0 in 2020, then slipped by 21.9% to $107000.0 in 2021, then jumped by 941.12% to $1.1 million in 2022, then increased by 12.93% to $1.3 million in 2023, then sank by 73.53% to $333000.0 in 2024.
- The last three Receivables - Other figures came in at $333000.0 (Q4 2024), $1.3 million (Q4 2023), and $700000.0 (Q1 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 333,000.00 |
| Dec 31, 2024 | 333,000.00 |
| Dec 31, 2023 | 1.26 Mn |
| Dec 31, 2023 | 1.26 Mn |
| Mar 31, 2023 | 700,000.00 |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 1.11 Mn |
| Dec 31, 2022 | 1.11 Mn |
| Sep 30, 2022 | 400,000.00 |
| Sep 30, 2022 | 400,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Jun 30, 2022 | 300,000.00 |
| Dec 31, 2021 | 107,000.00 |
| Dec 31, 2021 | 107,000.00 |
| Dec 31, 2020 | 137,000.00 |
| Dec 31, 2020 | 137,000.00 |
| Dec 31, 2019 | 184,000.00 |
| Dec 31, 2019 | 184,000.00 |
| Dec 31, 2018 | 140,000.00 |
| Dec 31, 2018 | 140,000.00 |